COMMENTARY
ACE2 activators for the treatment of COVID 19 patients
Rafael Rodríguez-Puertas PhD,
Corresponding Author
Rafael Rodríguez-Puertas PhD
Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain
Correspondence Rafael Rodríguez-Puertas, PhD, Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Barrio Sarriena s/n, 48940 Leioa, Vizcaya, Spain.
Email: [email protected]
Search for more papers by this author
Rafael Rodríguez-Puertas PhD,
Corresponding Author
Rafael Rodríguez-Puertas PhD
Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain
Correspondence Rafael Rodríguez-Puertas, PhD, Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Barrio Sarriena s/n, 48940 Leioa, Vizcaya, Spain.
Email: [email protected]
Search for more papers by this author
First published: 07 May 2020
No abstract is available for this article.
REFERENCES
- 1Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock. 2016; 3: 239-248. https://doi.org/10.1097/SHK.0000000000000633
- 2Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020. https://doi.org/10.1002/jmv.25785
- 3Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020; 382: 1653-1659. https://doi.org/10.1056/NEJMsr2005760
- 4Fang Y, Gao F, Liu Z. Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-κB and Nrf2 pathways. QJM. 2019; 112: 914-924. https://doi.org/10.1093/qjmed/hcz206
- 5Peiró C, Moncada S. Substituting angiotensin-(1-7) to prevent lung damage in SARSCoV2 infection? Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047297
- 6Xie X1, Chen J, Wang X, et al. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006; 78: 2166-2171. https://doi.org/10.1016/j.lfs.2005.09.038
- 7Hussain M, Jabeen N, Raza F, et al. Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. J Med Virol. 2020. https://doi.org/10.1002/jmv.25832
- 8Prata LO, Rodrigues CR, Martins JM, et al. Original research: ACE2 activator associated with physical exercise potentiates the reduction of pulmonary fibrosis. Exp Biol Med. 2017; 242: 8-21. https://doi.org/10.1177/1535370216665174
- 9da Silva Oliveira GL, de Freitas RM. Diminazene aceturate–An antiparasitic drug of antiquity: advances in pharmacology & therapeutics. Pharmacol Res. 2015; 102: 138-157. https://doi.org/10.1016/j.phrs.2015.10.005
- 10Velkoska E, Patel SK, Burrell LM. Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation. Curr Opin Nephrol Hypertens. 2016; 5: 384-395. https://doi.org/10.1097/MNH.0000000000000254
- 11Qaradakhi T, Gadanec LK, McSweeney KR, et al. The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases. Clin Exp Pharmacol Physiol. 2020; 47: 751-758. https://doi.org/10.1111/1440-1681.13251
- 12Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2: 69. https://doi.org/10.1186/1743-422X-2-69